63 related articles for article (PubMed ID: 10470183)
1. p53 determination in gynecological carcinomas: immunohistochemistry compared to luminometric immunoassay (LIA).
Heinze T; Greiner-Mai E; Lichtenegger W
Anticancer Res; 1999; 19(4A):2505-8. PubMed ID: 10470183
[TBL] [Abstract][Full Text] [Related]
2. Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time.
Heinze T; Jonas S; Kärsten A; Neuhaus P
Anticancer Res; 1999; 19(4A):2501-3. PubMed ID: 10470182
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.
Borg A; Lennerstrand J; Stenmark-Askmalm M; Fernö M; Brisfors A; Ohrvik A; Stål O; Killander D; Lane D; Brundell J
Br J Cancer; 1995 May; 71(5):1013-7. PubMed ID: 7734292
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of TP53 protein accumulation in human primary breast cancer: an analysis by luminometric immunoassay on 1491 tumor cytosols.
Berns EM; De Witte HH; Klijn JG; Willman K; Look MP; Meijer-Van Gelder ME; Benraad TJ; Foekens JA
Anticancer Res; 1997; 17(4B):3003-6. PubMed ID: 9329586
[TBL] [Abstract][Full Text] [Related]
5. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors.
Norberg T; Lennerstrand J; Inganäs M; Bergh J
Int J Cancer; 1998 Aug; 79(4):376-83. PubMed ID: 9699530
[TBL] [Abstract][Full Text] [Related]
6. P53 accumulation in primary breast cancer: a comparison between immunohistochemistry and a novel luminometric immunoassay.
Bombardieri E; Seregni E; Daidone MG; Benini E; Massaron S; Ferrari L; Di Fronzo G; Silvestrini R
Tumour Biol; 1998; 19(1):12-8. PubMed ID: 9422078
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cytosolic p53 protein levels in the female genital tract and breast, and their tumors.
Westhof G; Bader W; Greiner-Mai E; Hatzmann W
Tumour Biol; 2000; 21(3):123-34. PubMed ID: 10754462
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen (PSA) in breast and ovarian cancer.
Kucera E; Kainz C; Tempfer C; Zeillinger R; Koelbl H; Sliutz G
Anticancer Res; 1997; 17(6D):4735-7. PubMed ID: 9494598
[TBL] [Abstract][Full Text] [Related]
9. Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients.
Ferrero JM; Etienne MC; Formento JL; Francoual M; Rostagno P; Peyrottes I; Ettore F; Teissier E; Leblanc-Talent P; Namer M; Milano G
Br J Cancer; 2000 Jan; 82(1):171-7. PubMed ID: 10638986
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG
Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708
[TBL] [Abstract][Full Text] [Related]
11. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry.
Bonsing BA; Corver WE; Gorsira MC; van Vliet M; Oud PS; Cornelisse CJ; Fleuren GJ
Cytometry; 1997 May; 28(1):11-24. PubMed ID: 9136751
[TBL] [Abstract][Full Text] [Related]
12. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
13. Quantitative chemiluminescent immunoassay of p53: prognostic significance in 220 node-negative breast cancer tissue.
Dittadi R; Brazzale A; Mione R; Di Fresco S; Gatti C; Vinante O; Bassan F; Nascimben O; Gion M
Anticancer Res; 1997; 17(6D):4691-6. PubMed ID: 9494590
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study.
Broët P; Spyratos F; Romain S; Quillien V; Daver A; Ricolleau G; Rallet A; Toulas C; Asselain B
Br J Cancer; 1999 May; 80(3-4):536-45. PubMed ID: 10408864
[TBL] [Abstract][Full Text] [Related]
15. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas.
Bilyk OO; Pande NT; Buchynska LG
Exp Oncol; 2011 Sep; 33(3):150-6. PubMed ID: 21956468
[TBL] [Abstract][Full Text] [Related]
16. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
17. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer.
Elledge RM; Clark GM; Fuqua SA; Yu YY; Allred DC
Cancer Res; 1994 Jul; 54(14):3752-7. PubMed ID: 8033095
[TBL] [Abstract][Full Text] [Related]
18. p53 status in breast carcinomas revealed by FASAY correlates well with p53 protein accumulation determined by immunohistochemistry.
Smardová J; Vagunda V; Jandáková E; Vagundová M; Koukalová H; Kovarík J; Zaloudík J
Neoplasma; 1999; 46(6):384-9. PubMed ID: 10732868
[TBL] [Abstract][Full Text] [Related]
19. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
20. Quantification of p53 in epithelial ovarian cancer.
Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
